Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Announces Earnings Results

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) released its earnings results on Monday. The company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.62 by $0.04, Zacks reports. The firm had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.49 billion. Fresenius Medical Care AG & Co. KGaA had a net margin of 4.88% and a return on equity of 8.90%.

Fresenius Medical Care AG & Co. KGaA Trading Down 5.6%

Shares of FMS traded down $1.41 during trading hours on Tuesday, hitting $23.85. 747,586 shares of the stock were exchanged, compared to its average volume of 677,933. Fresenius Medical Care AG & Co. KGaA has a fifty-two week low of $20.02 and a fifty-two week high of $27.64. The business has a 50-day moving average of $23.39 and a 200-day moving average of $22.96. The firm has a market capitalization of $12.81 billion, a P/E ratio of 12.55, a price-to-earnings-growth ratio of 4.56 and a beta of 0.77. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.20 and a quick ratio of 0.86.

Wall Street Analysts Forecast Growth

Several brokerages have commented on FMS. Wall Street Zen downgraded shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Sanford C. Bernstein initiated coverage on Fresenius Medical Care AG & Co. KGaA in a report on Thursday, July 16th. They set a “market perform” rating for the company. Zacks Research raised Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “hold” rating in a research note on Monday, July 6th. Jefferies Financial Group upgraded shares of Fresenius Medical Care AG & Co. KGaA from a “strong sell” rating to a “moderate sell” rating in a research note on Friday, May 8th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday, July 17th. Six investment analysts have rated the stock with a Hold rating and five have assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Reduce” and an average price target of $23.95.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Institutional investors have recently bought and sold shares of the company. CIBC Private Wealth Group LLC raised its position in shares of Fresenius Medical Care AG & Co. KGaA by 398.2% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after acquiring an additional 1,103 shares in the last quarter. Arax Advisory Partners grew its stake in Fresenius Medical Care AG & Co. KGaA by 121.6% during the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after purchasing an additional 885 shares during the period. Kestra Advisory Services LLC acquired a new stake in Fresenius Medical Care AG & Co. KGaA during the fourth quarter worth approximately $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth approximately $58,000. Finally, Group One Trading LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter worth approximately $74,000. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.